A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
Status:
Terminated
Trial end date:
2017-05-08
Target enrollment:
Participant gender:
Summary
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD)
of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2,
multi center, randomized, placebo-controlled portion comparing the efficacy and safety of
OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP
alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell
lung cancer.